NCT00776594 - Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

December 31, 2014

Study Completion Date

September 30, 2016

Conditions

Prostate Cancer

Interventions

DRUG

Androgen Deprivation Therapy

leuprolide: 22.5mg given IM every 3 months for a total of 6 months or, goserelin acetate: 10.8mg given SC every 3 months for a total of 6 months

DRUG

bicalutamide

50mg orally daily for 6 months

DRUG

bevacizumab

15mg/ks given IV every three weeks for a total of 8 infusions over 6 months

Trial Locations (8)

Memorial Sloan-Kettering Cancer Center, New York

Johns Hopkins University, Baltimore

Karmanos Cancer Institute, Detroit

The University of Texas M D Anderson Cancer Center, Houston

Beth-Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Cancer Institute of New Jersey, New Brunswick

University of Wisconsin Carbone Cancer Center, Madison